Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
BrUOG360 trial: what clinicians have said so far
A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer
- NCT04253262 ↗
- Active, not recruiting
- Brown University
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on BrUOG360 (copanlisib plus rucaparib in metastatic castration-resistant prostate cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on BrUOG360 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X |
The trial
ClinicalTrials.gov- Official title
- A Phase Ib/II Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer
- Phase
- Phase 1/Phase 2
- Status
- Active, not recruiting
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- Rucaparib; Copanlisib
- Arms
- Dose Level -2 · Experimental
- Dose Level -1 · Experimental
- Dose Level 1 · Experimental
- Dose Level 2 · Experimental
- Dose Level 3 · Experimental
- Dose Level 4 · Experimental
- Enrollment
- 13
- Primary outcomes
- Maximum Tolerated Dose
- Response
- Sponsor
- Brown University with Rhode Island Hospital, The Miriam Hospital, Bayer, Clovis Oncology, Inc.
- Start
- Apr 3, 2020
- Primary completion
- Jan 2027 (estimated)
- Results posted
- No
- Registry record
- NCT04253262 · updated May 4, 2025